摘要
89Sr发射最大能量为1.46MeV的纯β射线,物理半衰期50.5d,很快在体内被成骨组织摄取,完全滞留在成骨性骨转移病灶内。在转移灶内的生物半衰期大于50d,而在正常骨内只有14d。在前列腺癌患者的肿瘤骨吸收剂量是正常骨的2~25倍。在骨肿瘤中的吸收剂量是(21±4)至(231±56)cGy/MBq。89Sr是前列腺癌骨转移患者骨痛的有效缓解药物,对骨疼痛的止痛有效率为80%。
Strontium-89(Sr-89)is a pure emitter with maximum beta energy of 1.46 MeV,average beta energy of 0.58 MeV,and a physical half-life of 50.5 days.It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases.Its biological half-life is 50 days at the metastatic sites,but about 14 days only in the normal bone.The dose of its Absorption in the tumor-bearing bone ranges from 21 ± 4 to 231 ± 56 cGy/MBq,2-25 times higher than in the normal bone.Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer,with analgesic effectiveness in 80%.
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2010年第3期269-272,共4页
National Journal of Andrology